About Neuromod
Neuromod is the global medical technology business behind bimodal neuromodulation tinnitus treatment device, Lenire.
Founding Neuromod
Dr. Ross O’Neill became interested in tinnitus during his Doctoral Research in Biomedical Engineering. Alarmed that a condition that affected 15% of the global population had such few treatment options, he knew change was needed.
Dr. O’Neill founded Neuromod to develop the Lenire tinnitus treatment device after completing his Ph.D. in auditory-somatic system interactions and continues his mission to advance tinnitus care for patients and their healthcare providers globally.
-
Dr. Manus Rogan PhD MBA Chairman
Dr. Manus Rogan PhD MBA ChairmanManus is a chemist who began his career in drug development before moving into business development and venture capital investment, establishing Fountain Healthcare Partners in the 2000’s to invest in groundbreaking technologies in the life science sector.
Linkedin -
Dr. Ross O’Neill Ph.D. MBA Executive Director
Dr. Ross O’Neill Ph.D. MBA Executive DirectorRoss is a Biomedical Engineer with a personal passion for developing neuromodulation therapies for hearing and auditory system disorders. Dr. O’Neill founded Neuromod in 2010 to develop the Lenire non-invasive bimodal neuromodulation device and advance tinnitus care for patients and their healthcare providers globally.
Linkedin -
Alessio Beverina Non-Executive Board Member
Alessio Beverina Non-Executive Board MemberAlessio is Co-Founder and General Partner of Panakès Partners, a Venture Capital fund dedicated to life sciences and headquartered in Milan, Italy with more than €250 million under management. Alessio has significant VC experience earned at Sofinnova Partners, one of Europe’s largest VCs, where he progressed from Analyst to Partner positions with European and American exposure.
He began his career in 1997 as a researcher at LETI, one of the most important European labs in the research field, before joining the central R&D group of STMicroelectronics. He graduated from Politecnico di Milano, with a degree in chemical engineering, specialising in the chemistry and physics of solid materials, and with an MBA from the Ecole Supérieure de Commerce de Paris (ESCP-EAP).
Alessio is a Kauffman Fellow and sits on the board of Alesi Surgical ltd, MMI spa and Neuromod Devices ltd. Alessio is also General Secretary of the Italian Tech Alliance.
Linkedin -
Susan Whichard Non-Executive Board Member
Susan Whichard Non-Executive Board MemberSusan has more than 30 years’ experience in the hearing industry, having worked as both a business executive and a practicing clinical audiologist. She served as president of the Academy of Doctors of Audiology (ADA) from 1992-1994. She has also held many leadership roles at companies such as GN Resound, InSound Medical and Phonak US. More recently, Susan started a consulting business focused on start-up innovation in hearing and healthcare.
Linkedin
Leadership Team
Ross is a Biomedical Engineer with a personal passion for developing neuromodulation therapies for hearing and auditory system disorders. Dr. O’Neill founded Neuromod in 2010 to develop the Lenire non-invasive bimodal neuromodulation device and advance tinnitus care for patients and their healthcare providers globally.
Linkedin
Prof. Brendan Conlon is currently the leading ENT Consultant at Blackrock Health with more than 25 years of experience treating disease of the ear in both adult and paediatric patients. He is also a Consultant ENT surgeon at St. James’s Hospital and Tallaght University Hospital.
He has fellowship training from the USA, France, and Australia. Brendan holds Fellowships of Otolaryngology and General Surgery at the Royal College of Surgeons in Ireland, a Masters in Medical Science from University College Dublin, and a MB BCh BAO BA MCh from Trinity College Dublin.
Prof. Conlon is Chief Medical Officer of Neuromod. He was the Primary Investigator of the company’s TENT (Treatment Evaluation of Neuromodulation for Tinnitus) clinical trials, TENT-A1 and TENT-A2.
Linkedin
Neuromod Devices’ Chief Scientific Officer, Prof. Hubert Lim is a Professor of Biomedical Engineering and Otolaryngology at the University of Minnesota.
Prof. Lim is also an Institute for Translational Neuroscience Scholar, Endowed Lions Professor in Otolaryngology, Bakken Professor for Engineering in Medicine, Director of the Bakken Medical Devices Center and Co-Director for the Center for Neural Engineering.
Linkedin
Diarmuid Flavin is Neuromod’s Chief Operating Officer. Diarmuid joined Neuromod in 2021 with more than 30 years of global leadership experience in a range of medical device, technology, and pharmaceutical companies.
Prior to Neuromod, Diarmuid worked at TE Connectivity, holding the role of Director Global Quality Compliance & Healthcare, and Site Director with the responsibility of overseeing the Galway campus’ 1,300 employees and associated operational and fiscal performance.
Diarmuid also served as Quality Director to Creganna Medical, which was later acquired by TE in 2016. He also spent five years at Irish biotech company Biosensia, as Chief Executive Officer and Chief Operating Officer.
Linkedin
Florian Elsaesser joined Neuromod in February 2020. From April 2022 he served as the company’s Chief Strategy and Corporate Development Officer until January 2024, when he became Neuromod’s CFO. Mr. Elsaesser has 12+ years hearing industry experience across various executive positions for Sivantos and Siemens Audiology.
Prior to Siemens Audiology’s acquisition by EQT, Florian held senior financial roles. Post-acquisition, Florian held senior business development and marketing roles in the newly rebranded Sivantos. Before joining Siemens, Florian worked for Siemens Energy, BMW, Mercedes-Benz, Spitzke and Lufthansa.
Florian holds a Master’s degree in Economics from Technische Universität Berlin and graduated in Management from Ecole Supérieure de Commerce de Paris (ESCP).
Linkedin
Eric Timm is President, Global Commercial Operations, and Chief Executive Officer of Neuromod USA Inc. Eric joined Neuromod in 2021 and has led the successful introduction of the Lenire tinnitus treatment device in the United States. Eric has held several leadership roles in the hearing health industry, most recently as the Chief Executive Officer of WS Audiology’s wholesale business. Prior to hearing health, he held multiple leadership positions at Cardinal Health, Bristol-Myers Squibb, and 3M.
Eric holds an MBA from the University of Wisconsin – Madison and a BA from Gustavus Adolphus College. Outside of work, Eric enjoys endurance sports, fishing, and motorcycle riding.
Tom Maher joined Neuromod as General Counsel in 2024, responsble for legal and contractual affairs, corporate transactions, governance, and corporate compliance.
Tom has more than twenty-five years of corporate legal and business experience in the international life sciences industry, including biopharma, biotech, and medtech.
Mr. Maher most recently served as Chief of Operations, Corporate Counsel and Company Secretary for Amarin Pharmaceuticals Ireland, and has a successful track record in three C-Suite positions for publicly traded companies.
LinkedinNeuromod Partnerships
We are proud to be working with a number of partners who share our vision for revolutionising tinnitus patient care.
Your Partner in Tinnitus Care
Neuromod is the redefining a new standard of tinnitus care together with a network of clinical partnerships. Contact our team to inquire about Neuromod Partnership.
FDA Approved Bimodal Tinnitus Treatment Device
Lenire is the first and only FDA Approved bimodal neuromodulation tinnitus treatment device.
